| Literature DB >> 30874603 |
Enza Di Gregorio1, Giuseppe Ferrauto1, Stefania Lanzardo1, Eliana Gianolio1, Silvio Aime2,3.
Abstract
Breast Cancer is the most diffuse cancer among women and the treatment outcome is largely determined by its early detection. MRI at fixed magnetic field is already widely used for cancer detection. Herein it is shown that the acquisition of proton T1 at different magnetic fields adds further advantages. In fact, Fast Field Cycling Nuclear Magnetic Resonance Dispersion (FFC-NMRD) profiles have been shown to act as a high -sensitivity tool for cancer detection and staging in ex vivo murine breast tissues collected from Balb/NeuT mice. From NMRD profiles it was possible to extract two new cancer biomarkers, namely: (i) the appearance of 14N-quadrupolar peaks (QPs) reporting on tumor onset and (ii) the slope of the NMRD profile reporting on the progression of the tumor. By this approach it was possible to detect the presence of tumor in transgenic NeuT mice at a very early stage (5-7 weeks), when the disease is not yet detectable by using conventional high field (7 T) MRI and only minimal abnormalities are present in histological assays. These results show that, NMRD profiles may represent a useful tool for early breast cancer detection and for getting more insight into an accurate tumor phenotyping, highlighting changes in composition of the mammary gland tissue (lipids/proteins/water) occurring during the development of the neoplasia.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30874603 PMCID: PMC6420649 DOI: 10.1038/s41598-019-41154-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Axial T2w MR Images of Balb/C-NeuT mice at different growth stages and health Balb/c control (white arrows indicates breast/tumor regions).
Figure 2(A) NMRD profiles of breast cancer at different stages (7, 15, 21 and 30 weeks) and of control healthy breast tissue (Mean ± SD of at least 8 independent specimens). (B) Magnification of the NMRD profiles in the region 0.1–10 MHz range; (C) Representative QPs obtained by subtracting background (5–7w, 15w and 21–30w), (D) Linear fitting of NMRD profiles (in the log/log scale) and (E) slope of the linear fitting for control and NeuT mice at different stage of tumor growth (Mean ± SD) (*P-value < 0.1).
Figure 3Representative Hematoxylin/Eosin staining of breast tissue at different stages: (A) healthy Balb/c mouse, (B) NeuT mouse at 7w, (C) NeuT mouse at 15w, (D) NeuT mouse at 21w and (E) NeuT mouse at 30w (Magnification 20x).
Figure 4(A) NMRD profiles of specimens containing cross-linked BSA and oil at different ratio; (B) Linear fitting of NMRD profiles (in the log/log scale); (C) Slope of the linear curves vs. BSA/oil ratio.